Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial. (Q39155626)
Jump to navigation
Jump to search
scientific article published on 16 May 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial. |
scientific article published on 16 May 2017 |
Statements
Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial (English)
Felix Alt
Pee-Win Chong
1 reference
1 reference
1 reference
1 reference